Ascelia Pharma suffers another significant stock plunge after the FDA confirmed its requirement for a new study for the drug candidate Orviglance, following a previous decline of 75 percent after a rejection in July. #aktiekollaps #FDA #AsceliaPharma (translated)
www.di.se
Nytt ras efter kurskollapsen
